NASDAQ:ATYR aTyr Pharma Q3 2024 Earnings Report $0.50 +0.01 (+1.42%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast aTyr Pharma EPS ResultsActual EPS-$0.23Consensus EPS -$0.22Beat/MissMissed by -$0.01One Year Ago EPSN/AaTyr Pharma Revenue ResultsActual RevenueN/AExpected Revenue$0.13 millionBeat/MissN/AYoY Revenue GrowthN/AaTyr Pharma Announcement DetailsQuarterQ3 2024Date11/7/2024TimeAfter Market ClosesConference Call DateThursday, November 7, 2024Conference Call Time4:00PM ETUpcoming EarningsaTyr Pharma's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) aTyr Pharma Earnings HeadlinesATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung DiseaseSeptember 2 at 12:44 PM | rttnews.comaTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of EfzofitimodSeptember 2 at 1:32 AM | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 3 at 1:00 AM | Profits Run (Ad)aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis StudySeptember 1 at 4:50 PM | quiverquant.comQaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary SarcoidosisSeptember 1 at 4:36 PM | globenewswire.comaTyr Pharma Inc 471AAugust 12, 2026 | morningstar.comMSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors. The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas. Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
